Infrared therapy noncovered
This article was originally published in The Gray Sheet
Executive Summary
More than 4,000 comments from patients and clinicians supporting market-leading Anodyne infrared therapy could not sway CMS to reverse its proposed noncoverage decision for its use to treat peripheral sensory neuropathy, wounds, skin ulcers and related symptoms (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS' final national coverage decision, released Oct. 24, cites lack of evidence of the treatment's durability, poor methodology in studies with positive results, significant placebo effect and concerns about adverse events reported to FDA...
You may also be interested in...
In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.